In Body (KRX: 041830)
Who is buying In Body?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩4.5bn ($3M) of In Body, the 77th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net bought ₩2.7bn ($2M) and retail investors net sold ₩7.0bn ($5M) over the same window. Foreigners were net buyers on 14 of the 20 sessions.
Foreign investors hold 33.5% of In Body's listed shares (KRX ownership data as of Oct 13, 2026), up from 32.9% twenty sessions earlier and 38.5% a year ago.
The stock closed at ₩50,100 on Oct 13, 2026: -14.36% over 20 sessions, +52.98% year-to-date, +61.35% over one year. The 52-week range is ₩26,200 – ₩73,500.
At ₩50,100 the stock trades at 11.07× 12-month-forward consensus earnings (2 analysts), 10.69× on FY2027 estimates. The trailing P/E published by KRX is 20.68×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩50,100 | +₩0.6bn | +₩0.4bn | ₩-0.6bn |
| 2026-10-12 | ₩51,100 | +₩0.0bn | +₩0.2bn | ₩-0.3bn |
| 2026-10-08 | ₩51,000 | ₩-1.4bn | +₩0.7bn | +₩0.6bn |
| 2026-10-07 | ₩53,100 | ₩-0.9bn | +₩0.3bn | +₩0.6bn |
| 2026-10-06 | ₩52,300 | ₩-0.2bn | +₩0.4bn | ₩-0.2bn |
| 2026-10-02 | ₩52,100 | ₩-0.1bn | ₩-0.2bn | +₩0.3bn |
| 2026-10-01 | ₩53,400 | +₩0.3bn | ₩-0.2bn | ₩-0.1bn |
| 2026-09-30 | ₩52,600 | +₩0.6bn | ₩-0.8bn | +₩0.2bn |
| 2026-09-29 | ₩53,800 | +₩0.5bn | ₩-0.2bn | ₩-0.2bn |
| 2026-09-28 | ₩54,300 | +₩0.6bn | ₩-0.3bn | ₩-0.3bn |
| 2026-09-23 | ₩53,200 | +₩0.7bn | ₩-0.5bn | ₩-0.1bn |
| 2026-09-22 | ₩54,200 | +₩1.9bn | ₩-1.9bn | ₩-0.2bn |
| 2026-09-21 | ₩57,300 | +₩0.6bn | ₩-0.2bn | ₩-0.3bn |
| 2026-09-18 | ₩57,500 | +₩0.1bn | ₩-0.4bn | +₩0.3bn |
| 2026-09-17 | ₩58,100 | ₩-0.5bn | +₩0.3bn | +₩0.1bn |
| 2026-09-16 | ₩57,800 | ₩-0.3bn | +₩0.1bn | +₩0.2bn |
| 2026-09-15 | ₩58,300 | +₩1.2bn | +₩5.8bn | ₩-7.0bn |
| 2026-09-14 | ₩56,700 | +₩0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-09-11 | ₩57,600 | +₩0.2bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-10 | ₩58,300 | +₩0.5bn | ₩-0.6bn | ₩-0.0bn |
| 2026-09-09 | ₩58,500 | +₩0.6bn | ₩-0.8bn | +₩0.1bn |
| 2026-09-08 | ₩58,400 | +₩1.2bn | ₩-1.3bn | +₩0.1bn |
| 2026-09-07 | ₩60,000 | ₩-0.4bn | ₩-0.1bn | +₩0.4bn |
| 2026-09-04 | ₩61,100 | ₩-0.7bn | +₩0.7bn | ₩-0.1bn |
| 2026-09-03 | ₩59,600 | ₩-1.2bn | +₩1.1bn | +₩0.3bn |
| 2026-09-02 | ₩58,900 | +₩0.3bn | +₩0.3bn | ₩-0.5bn |
| 2026-09-01 | ₩61,100 | ₩-2.0bn | +₩3.6bn | ₩-1.7bn |
| 2026-08-31 | ₩60,200 | +₩1.4bn | +₩0.4bn | ₩-1.6bn |
| 2026-08-28 | ₩60,300 | +₩0.7bn | ₩-0.6bn | +₩0.2bn |
| 2026-08-27 | ₩60,500 | +₩0.1bn | ₩-1.5bn | +₩1.4bn |
| 2026-08-26 | ₩60,300 | ₩-1.0bn | +₩0.4bn | +₩0.5bn |
| 2026-08-25 | ₩60,900 | ₩-1.6bn | +₩0.1bn | +₩1.4bn |
| 2026-08-24 | ₩62,900 | ₩-3.1bn | +₩2.6bn | +₩0.5bn |
| 2026-08-21 | ₩59,800 | +₩1.1bn | +₩1.1bn | ₩-2.0bn |
| 2026-08-20 | ₩62,000 | ₩-0.7bn | ₩-0.3bn | +₩1.0bn |
| 2026-08-19 | ₩62,400 | ₩-2.9bn | +₩2.2bn | +₩0.7bn |
| 2026-08-18 | ₩61,100 | ₩-0.4bn | +₩0.1bn | +₩0.7bn |
| 2026-08-14 | ₩64,400 | +₩3.9bn | ₩-3.3bn | ₩-0.3bn |
| 2026-08-13 | ₩66,200 | +₩3.4bn | ₩-0.9bn | ₩-2.1bn |
| 2026-08-12 | ₩67,400 | +₩3.7bn | ₩-1.7bn | ₩-1.9bn |
| 2026-08-11 | ₩69,900 | +₩1.6bn | ₩-0.6bn | ₩-0.5bn |
| 2026-08-10 | ₩70,000 | ₩-0.4bn | ₩-0.8bn | +₩1.4bn |
| 2026-08-07 | ₩70,800 | ₩-8.2bn | +₩7.7bn | +₩0.1bn |
| 2026-08-06 | ₩70,000 | +₩0.4bn | +₩5.0bn | ₩-5.5bn |
| 2026-08-05 | ₩56,700 | ₩-0.1bn | ₩-1.0bn | +₩1.4bn |
| 2026-08-04 | ₩57,400 | ₩-2.3bn | +₩2.5bn | ₩-0.2bn |
| 2026-08-03 | ₩50,000 | +₩0.2bn | +₩0.4bn | ₩-0.6bn |
| 2026-07-31 | ₩46,200 | +₩0.7bn | ₩-0.4bn | ₩-0.3bn |
| 2026-07-30 | ₩46,650 | ₩-0.0bn | +₩0.3bn | ₩-0.2bn |
| 2026-07-29 | ₩49,400 | ₩-1.2bn | +₩1.9bn | ₩-0.7bn |
| 2026-07-28 | ₩50,300 | ₩-2.0bn | +₩2.4bn | ₩-0.4bn |
| 2026-07-27 | ₩50,500 | ₩-1.4bn | +₩1.3bn | +₩0.1bn |
| 2026-07-24 | ₩47,500 | +₩0.9bn | ₩-0.7bn | ₩-0.3bn |
| 2026-07-23 | ₩49,100 | +₩1.8bn | ₩-1.0bn | ₩-0.7bn |
| 2026-07-22 | ₩49,700 | ₩-1.3bn | ₩-0.8bn | +₩2.0bn |
| 2026-07-21 | ₩53,400 | ₩-2.6bn | +₩3.4bn | ₩-0.8bn |
| 2026-07-20 | ₩50,900 | ₩-0.0bn | ₩-0.4bn | +₩0.2bn |
| 2026-07-16 | ₩54,200 | ₩-1.3bn | +₩0.2bn | +₩0.5bn |
| 2026-07-15 | ₩55,500 | ₩-1.2bn | +₩1.0bn | +₩0.0bn |
| 2026-07-14 | ₩52,400 | ₩-0.1bn | +₩0.4bn | ₩-0.6bn |
| 2026-07-13 | ₩51,600 | ₩-1.0bn | +₩1.0bn | ₩-0.1bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩0.6bn | +$0M | +₩0.4bn | ₩-0.6bn |
| 5 days | ₩-1.9bn | $-1M | +₩2.1bn | +₩0.2bn |
| 20 days | +₩4.5bn | +$3M | +₩2.7bn | ₩-7.0bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying In Body stock?
Over the last 5 sessions foreign investors net sold ₩1.9bn ($1M) of In Body; over 60 sessions they net sold ₩9.2bn ($7M); since Jan 1, 2026 they net sold ₩34.9bn ($26M). Over 20 sessions the stock is the 77th largest foreign net purchase among 1828 KOSDAQ stocks.
How much of In Body do foreign investors own?
Foreign investors own 33.5% of In Body's shares as of Oct 13, 2026, versus 38.5% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩2.7bn ($2M) and retail investors net sold ₩7.0bn ($5M) of In Body. Retail investors have been supplying the shares that foreigners and institutions are buying.
Is In Body listed on KOSPI or KOSDAQ?
In Body (인바디) trades on KOSDAQ under KRX code 041830 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.5B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩170bn ($128M) | – | ₩38bn ($29M) | ₩37bn ($27M) |
| 2024 | ₩204bn ($153M) | +20.00% | ₩37bn ($28M) | ₩33bn ($25M) |
| 2025 | ₩234bn ($175M) | +14.40% | ₩37bn ($28M) | ₩30bn ($22M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.